Os Therapies Inc (OSTX) — 8-K Filings

8-K Filings (23)

• OS Therapies Inc. Files 8-K on Officer Changes and Shareholder Votes — Oct 21, 2025 Risk: medium
  On October 21, 2025, OS Therapies Inc. filed an 8-K report detailing several key events. The filing includes information regarding the departure of directors or
• OS Therapies Inc. Files 8-K — Sep 30, 2025 Risk: low
  OS Therapies Inc. filed an 8-K on September 30, 2025, reporting on other events and financial statements. The filing does not detail specific transactions or fi
• OS Therapies Inc. Files 8-K with Material Agreements — Sep 2, 2025 Risk: medium
  On September 2, 2025, OS Therapies Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and o
• OS Therapies Terminates Material Agreement — Aug 26, 2025 Risk: medium
  On August 25, 2025, OS Therapies Inc. filed an 8-K report indicating the termination of a material definitive agreement. The filing also noted other events and
• OS Therapies Inc. Files 8-K on Financials — Aug 19, 2025 Risk: low
  OS Therapies Inc. filed an 8-K on August 19, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and
• OS Therapies Inc. Files 8-K with Corporate Updates — Aug 15, 2025 Risk: low
  OS Therapies Inc. filed an 8-K on August 15, 2025, reporting amendments to its Articles of Incorporation or Bylaws and filing financial statements and exhibits.
• OS Therapies Inc. Files 8-K: Material Agreement, Equity Sales — Jul 14, 2025 Risk: medium
  On July 11, 2025, OS Therapies Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The company also
• OS Therapies Inc. Files 8-K: Material Agreement & Equity Sales — Jun 27, 2025 Risk: medium
  On June 26, 2025, OS Therapies Inc. entered into a material definitive agreement and reported unregistered sales of equity securities. The company, incorporated
• OS Therapies Inc. Files 8-K for Material Agreement & Equity Sales — Jun 24, 2025 Risk: medium
  On June 23, 2025, OS Therapies Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company also
• OS Therapies Inc. Files 8-K on Financials — May 16, 2025 Risk: low
  On May 16, 2025, OS Therapies Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as fi
• OS Therapies Inc. Completes Acquisition, Reports Equity Sales — Apr 15, 2025 Risk: medium
  On April 9, 2025, OS Therapies Inc. reported the completion of an acquisition. The filing also disclosed unregistered sales of equity securities and other event
• OS Therapies Files 8-K on Shareholder Votes & Financials — Apr 9, 2025 Risk: low
  OS Therapies Inc. filed an 8-K on April 9, 2025, reporting on matters submitted to a vote of security holders and financial statements/exhibits. The filing does
• OS Therapies Files 8-K for March 31, 2025 — Apr 2, 2025 Risk: low
  OS Therapies Inc. filed an 8-K on April 2, 2025, reporting events as of March 31, 2025. The filing primarily concerns financial statements and exhibits, with no
• OS Therapies Files 8-K: Agreements, Equity Sales, Officer Changes — Jan 29, 2025 Risk: medium
  On January 28, 2025, OS Therapies Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company al
• OS Therapies to Acquire Ocuphire Pharma for $0.70/Share — Jan 15, 2025 Risk: medium
  OS Therapies Inc. announced on January 14, 2025, that it has entered into a definitive agreement to acquire all outstanding shares of Ocuphire Pharma, Inc. for
• OS Therapies Inc. Files 8-K: Material Agreement & Equity Sales — Jan 14, 2025 Risk: medium
  On January 10, 2025, OS Therapies Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company al
• OS Therapies Inc. Files 8-K for Material Agreement — Jan 3, 2025 Risk: medium
  On December 31, 2024, OS Therapies Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and o
• OS Therapies Inc. Files 8-K: Agreements, Equity Sales, Bylaw Changes — Dec 30, 2024 Risk: medium
  On December 24, 2024, OS Therapies Inc. entered into a Material Definitive Agreement. The company also reported on unregistered sales of equity securities and a
• OS Therapies Files 8-K on Financials — Nov 15, 2024 Risk: low
  On November 15, 2024, OS Therapies Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along wi
• OS Therapies Inc. Files 8-K: Material Agreement, Equity Sales — Nov 1, 2024 Risk: medium
  On October 31, 2024, OS Therapies Inc. entered into a Material Definitive Agreement. The company also reported on Unregistered Sales of Equity Securities and fi
• OS Therapies Inc. Appoints New CMO and Director — Oct 28, 2024 Risk: medium
  OS Therapies Inc. announced on October 28, 2024, the departure of director Dr. David J. E. Smith and the appointment of Dr. David J. E. Smith as Chief Medical O
• OS Therapies Inc. Files 8-K with Financials — Aug 22, 2024 Risk: low
  On August 22, 2024, OS Therapies Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no other specific events detail
• OS Therapies Files 8-K on Financials — Aug 15, 2024 Risk: low
  OS Therapies Inc. filed an 8-K on August 15, 2024, reporting on its Results of Operations and Financial Condition. The filing provides information regarding the

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX